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Summary The present study describes a comparison of two potent immunotoxins which utilise an identical
targeting component, a monoclonal antibody (SEN7) specific for small cell lung cancer (SCLC), conjugated to
two different effector components, blocked ricin (bR) and Pseudomonas exotoxin A (PE). SEN7 recognises a
novel epitope on the neural cell adhesion molecule (NCAM) which is highly associated with SCLC. The
immunotoxins SEN7-PE and SEN7-bR were selectively and potently active against a number of SCLC cell
lines, of both classic and variant morphologies, inhibiting the incorporation of [3H]leucine with IC50 values
ranging between 22 pM and 85 pM and between 7pM and 62pM for SEN7-PE and SEN7-bR respectively.
Intoxication by both immunotoxins proceeded rapidly following short 2 h lag phases; the initial rates of
protein synthesis inhibition occurred with t50 values of 6.5 h for SEN7-PE and 5.5 h for SEN7-bR. Monensin
drastically enhanced the cytotoxic activity of the weakly active SEN7-ricin A-chain by 2,100-fold and of
SEN7-bR by 80-fold but had no effect on SEN7-PE. In limiting dilution assays, four and more than 4.5 logs
of clonogenic SW2 tumour cells were selectively eliminated from the cultures during continuous exposure to
the immunotoxins SEN7-PE and SEN7-bR respectively, while antigen-negative cells required up to 1,000-fold
more drug for a similar cell kill. SW2 cells surviving SEN7-bR treatment in the cultures did not express
NCAM and consequently were not selectively killed by SEN7 immunotoxins. SW2 cells surviving continuous
exposure to SEN7-PE showed no alteration in NCAM expression but were more resistant to intoxication
mediated by PE. These cells were still sensitive to SEN7-bR.
Small cell lung cancer (SCLC) is one of the most fatal
malignancies and presents as disseminated disease in over
65% of cases. Despite the initial sensitivity of SCLC to
radiation and chemotherapy, novel treatment modalities
appear necessary since the emergence of a drug-resistant
phenotype is the primary reason for failure of conventional
therapy to cure this disease (Carney & de Lei, 1988).
The use of immunotoxins as adjuncts to conventional
chemotherapeutic drugs has received considerable attention
because these agents have mechanisms of action distinct from
conventional chemotherapy and those cancer cells that are
naturally resistant or acquire resistance to chemotherapeutic
drugs will not be cross-resistant to toxin-based therapies
(FitzGerald et al., 1987). The plant toxin ricin and the
bacterial toxin Pseudomonas exotoxin A (PE) act by arresting
the synthesis of proteins in eukaryotic cells employing
different mechanisms of action. The A-chain of ricin has an
irreversible N-glycosidase activity and acts on the 60S
ribosomal subunit (Endo et al., 1987). The catalytic domain
of PE has ADP-ribosyl transferase activity which is essen-
tially irreversible under physiological conditions and acts on
the elongation factor 2 (Iglewski et al., 1977). The process of
intoxication is promoted by ubiquitous expression of cell-
surface receptors, terminal galactosyl residues for ricin
(Blakey & Thorpe, 1988) and the M2-macroglobulin receptor
for PE (Kounnas et al., 1992). To increase their selectivity,
these toxins must be modified so that interactions through
the natural receptors are diminished or abolished. Blocked
ricin (bR) is a derivative in which the galactose binding sites
of the B-chain are blocked by chemical modification resulting
in a 3,500-fold lower binding affinity (Lambert et al.,
1991a,b). With PE modification occurs most efficiently when
the MAb is coupled to domain I via a thioether linkage
which sterically blocks its cell-binding activity (Morgan et al.,
1990; FitzGerald et al., 1990). Both bR and PE blocked by a
thioether linkage have intact translocation and catalytic
domains. If a target antigen is internalised by the cell
modification can be accomplished through removal of the
B-chain of ricin (Blakey & Thorpe, 1988) or through
genetically deleting domain I of PE (Pastan & FitzGerald,
1991). The MAb is then coupled directly to the A-chain or to
domain II respectively. If a target antigen is fixed to the cell
surface, internalisation of immunotoxins can only occur
when whole toxin derivatives of ricin or PE are used which,
although weakened by chemical modifications, still bind to
their natural receptors.
For delivering toxins to SCLC cells, monoclonal antibodies
(MAbs) are available, which have been grouped into clusters
based on their reactivity with lung tumours, cell lines and
normal tissue. Immunotoxins which employ these MAbs
have demonstrated substantial cytotoxic potency against
SCLC cell lines in preclinical studies (Wawrzynczak et al.,
1990; 1991; Derbyshire et al., 1992a; Zangemeister-Wittke et
al., 1993a,b) as well as in the clinic (Lynch et al., 1993).
MAbs belonging to the major cluster 1 were found to be
directed against the neural cell adhesion molecule (NCAM)
(Souhami et al., 1991), a member of the immunoglobulin
superfamily which is expressed with high frequency on brain
tumours, neuroblastomas, Wilms' tumour and SCLC (Patel
et al., 1990; Moolenaar et al., 1990; Carbone et al., 1991).
Multiple NCAM isoforms have been found representing a
combination of cell type and developmentally stage-specific
splicing and sialylation (Rothbard et al., 1982; Rougon et al.,
1982). The MAb SEN7, a previously described mouse IgGI
(Waibel et al., 1993), recognises an epitope on NCAM that is
homogeneously expressed on all SCLC cells. In contrast to
previously described cluster 1 MAbs, SEN7 does not react
with lymphoid tissue and peripheral blood lymphocytes and
thus might prove a promising candidate for the selective
delivery of highly cytotoxic agents to SCLC.
In the present study the NCAM-specific MAb SEN7 was
evaluated for its potential to make potent and selective
immunotoxins against SCLC. Because in previous studies
ricin A-chain immunotoxins directed against NCAM on
SCLC could not prove potent cytotoxic agents (Wawrzyn-
czak et al., 1991; Derbyshire et al., 1992b), the whole toxin
molecules bR and PE were used for immunotoxin prepara-
tions. In a series of tissue culture experiments the cytotoxic
properties of SEN7-bR and of SEN7-PE were examined in
detail.
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Materials and methods
Cell lines and tissue culture
The following SCLC cell lines were kindly provided: SW2
(S.D. Bernal, Dana Farber Cancer Institute, Boston, MA,
USA); OHI, OH3 (S.B. Baylin, Johns Hopkins University
Medical Institute, Baltimore, MD, USA); DC571.38, H249,
N417 (D.N. Carney, Mater Misericordiae Hospital, Dublin,
Ireland), LX1 (A.E. Bogden, Mason Research Institute,
Worcester, MA, USA); H60 (A. Gazdar and J. Minna, NCI,
Bethesda, MD, USA). The squamous lung cancer cell line
U1752 was obtained from J. Bergh, University of Uppsala,
Sweden. Cell lines were grown in RPMI-1640 (Gibco, Life
Technologies, UK) containing 4 mM L-glutamine supple-
mented with 10% fetal calf serum at 37°C in a humidified
atmosphere. Cell lines were maintained in exponential growth
as asynchronous cultures and were found to be free of
mycoplasma infection.
Monoclonal antibodies and immunotoxins
The monoclonal antibody (MAb) SEN7, a mouse IgG1
recognising an epitope on the neural cell adhesion molecule
(NCAM) (Waibel et al., 1993), and the isotype-matched
control MAb SJ25-Cl (anti-CD19; Sigma, St Louis, MO,
USA) were used for immunotoxin preparations. The isotype-
matched control immunotoxin anti-B4-blocked ricin (bR)
(anti-CD19; Shah et al., 1993) was supplied by Immunogen
(Cambridge, MA, USA). The mouse IgGl SEN36, recognis-
ing a different cluster 1 (NCAM) epitope (Wawrzynczak et
al., 1991), was used as control for immunofluorescence
analyses. The mouse IgGI SEN31, recognising the cluster 5a
antigen (Zangemeister-Wittke et al., 1993b), was used as
control in the internalisation assay. MAbs SEN7, SEN36 and
SEN31 were purified from hybridoma supernatants by pro-
tein A affinity chromatography in 0.1 M Tris-HCI buffer
pH 8.5 containing 3 M sodium chloride. The antibodies were
eluted with 50mM sodium phosphate buffer (pH 6.0) con-
taining 150 mM sodium chloride, then subjected to ion-
exchange chromatography on Mono S HR5/5 (Pharmacia,
Sweden) and eluted with a 0-500mM gradient of sodium
chloride in a buffer of 50mM sodium phosphate. Ricin A-
chain (Inland Laboratories, Austin, TX, USA) was attached
to SEN7 and SJ25-C1 via disulphide bonds according to the
procedure described by Cumber et al. (1985). Briefly, MAbs
were reacted with N-succinimidyl 3-(pyridyldithio) pro-
pionate (SPDP) (Pierce, Rockford, IL, USA) to introduce an
average of two groups per antibody. Derivatised MAbs were
reacted overnight with a 2.5-fold molar excess of freshly
reduced ricin A-chain and the mixtures were applied to a
column of Sephacryl S200HR (Pharmacia, Sweden).
SEN7-blocked ricin (bR) was prepared essentially as
previously described (Lambert et al., 1991b). Briefly, purified
SEN7 in PBS containing 1 mM EDTA was reacted with a
5-fold molar excess of succinimidyl 4-(N-maleimidomethyl)-
cyclohexane carboxylate (SMCC) (Pierce) and incubated at
30°C for 30 min. The antibody was separated from the
unreacted cross-linker on a Fast Desalting HR10/10 column
(Pharmacia, Sweden). Blocked ricin (bR) was reduced in PBS
(pH 6.8) containing 3 mM dithiothreitol (DTT) (Sigma) and
3 mM EDTA at 4°C for 20 h. DTT was separated from bR
on a Fast Desalting HR10/10 column equilibrated with 5 mm
sodium acetate pH 4.7. Modified SEN7 in PBS was mixed
with a 3-fold molar excess of freshly reduced bR and the
reaction mixture was allowed to stand overnight at 4°C.
SEN7-bR was separated from unconjugated antibody and
unconjugated bR by ion-exchange chromatography on a
Mono S HR5/5 column in 50 mM sodium acetate (pH 5.0)
followed by immunoaffinity chromatography on a mono-
clonal anti-ricin column in 100 mM phosphate (pH 7.0).
SEN7-bR was eluted with 100 mM glycine-HCI (pH 2.7) and
neutralised with sodium phosphate.
For the preparation of SEN7-Pseudomonas exotoxin A
(PE) and SJ25-C1-PE, purified MAbs at 5-10mgml-' were
mixed with a 3-fold molar excess of 2-iminothiolane hydro-
chloride in 100 mM sodium phosphate (pH 8.0) containing
2 mM EDTA and incubated at room temperature for 1 h. PE
(Pseudomonas aeruginosa production strain PA103, Swiss
Serum and Vaccine Institute, Bern, Switzerland) at 5 mgml-'
in 100 mM sodium phosphate (pH 7.0) containing 0.3 mg
ml-' NAD and 3 mM EDTA was mixed with a 3-fold molar
excess of SMCC and incubated at room temperature for
30min. Derivatised proteins were separated from the reac-
tants on a Fast Desalting HR1O/10 column equilibrated with
100 mM sodium phosphate (pH 8.0). SEN7 was allowed to
react with a 4-fold molar excess of PE for 20 h at room
temperature and the immunotoxin was purified by successive
chromatography on MonoQ HR5/5 in 20mM Tris-HCI
(pH 7.6) and Sephacryl S-200HR columns (Pharmacia,
Sweden). The resulting immunotoxin preparations, which
consisted predominantly of 1:1 conjugates of antibodies and
toxins as determined by SDS-PAGE under non-reducing
conditions (Fast Electrophoresis System, Pharmacia,
Sweden), were pooled and stored frozen at - 70C in PBS.
Antibody internalisation assay
The internalisation capacity of SEN7 was evaluated by an
immunofluorescence cytochemical assay designed to visualise
internalized antibody without interference from surface-
bound antibody as described by Chang et al. (1992) with
modifications. Approximately 5 x I05 SW2 cells in 1.5ml
microfuge tubes were washed in cold PBS-1% BSA followed
by incubation with 0.1 gM SEN7 or SEN31 control antibody
at 4°C for 1 h. The cell suspensions were warmed to 37°C for
45 min to allow the surface-bound antibody to internalise
into the cells. After washing in PBS.-1% BSA, the cells were
incubated with an acid buffer (pH 2.8) containing 0.1 M
sodium chloride and 50 mM glycine-HCl at 0'C for 15 min,
then washed in PBS-1% BSA, and incubated with PBS
containing 3 mgml-' normal goat '-globulin and 0.1%
saponin for 15 min. The cells were incubated for 1 h with
rhodamine-labelled goat anti-mouse F(ab')2 IgG fragments
(Jackson ImmunoRes. Lab., PA, USA) in 3 mgml-' normal
goat globulin-0. 1% saponin-PBS, washed and fixed again
with 3.7% formaldehyde for 10min and finally washed in
PBS. Cytospin preparations of 105 cells were mounted in
Vectashield medium (Vector Laboratories, Burlingame, CA,
USA) and analysed using a confocal laser microscope (LMS,
Zeiss, Germany).
FITC labelling ofMAbs
The MAbs SEN7 and SEN36 were dialysed against 0.1 M
borate buffer pH9.0, and allowed to react with a 15-fold
(SEN7) or 25-fold (SEN36) molar excess of fluorescein
isothiocyanate (FITC) (Fluka, Buchs, Switzerland) dissolved
in dimethylformamide for 6h at 4°C. The conjugate was
separated from unreacted compounds by gel filtration on a
Fast Desalting HRIO/10 column (Pharmacia, Sweden).
Immunofluorescence staining andFACS analyses
SW2 cells (106) were incubated with 100 ll of PBS-1% BSA
containing 0.02% sodium azide and 1.5 Ztg of FITC-labelled
SEN7 or SEN36 at OC for I h. The cells were washed in
PBS-1% BSA containing sodium azide and subjected to
FACS analysis. A Becton Dickinson FACScan equipped with
a 4 log decade full-scale amplifier gain and an analogue-to-
digital converter with 1024 channels was used to analyse the
mean fluorescence intensities of 10,000 cells.
Cell-binding analyses ofimmunotoxins
The cell-binding activities of FITC-labelled SEN7 and the
SEN7 immunotoxins on SW2 cells were compared in a com-
petition binding assay essentially as described by Lambert et
al. (199lb). Briefly, S x I05 SW2 cells were incubated at 0'C
for 1 h in 100gil of PBS-1% BSA, 1 nM FITC-labelled34 U. ZANGEMEISTER-WITTKE et al.
SEN7 and varying concentrations of either unlabelled SEN7
or immunotoxins. Fluorescence staining of cells was quan-
titated by FACS analyses.
Cytotoxicity assays
The cytotoxicity assays in tissue culture were performed
using [3H]leucine incorporation and limiting dilution clono-
genic assays essentially as previously described (Zangemeis-
ter-Wittke et al., 1993a). Briefly, 2 x 104 cells in leucine-free
tissue culture medium were seeded into 96-well tissue culture
plates. Subsequently, different dilutions of the immunotoxins
or unconjugated toxins were added to the wells to reach a
final volume of 200 lI. The plates were incubated for 20 h at
37°C, pulsed with 1 ACi per well [3H]leucine for 4 h and
harvested onto glass-fibre discs. The concentration at which
[3H]leucine incorporation was inhibited to 50% compared
with controls that did not receive immunotoxin was deter-
mined in quadruplicates. Antigen specificity of cytotoxicity
mediated by the SEN7 immunotoxins was assessed by prein-
cubation of cells for 1 h with excess amounts (1 JAM) of
unconjugated SEN7 in the cultures. In some experiments, the
carboxylic ionophore monensin and the lysosomotropic
amines ammonium chloride and chloroquine were tested for
their potentiating capacities and included in both test and
control cultures. The kinetics of protein synthesis inhibition
was measured in the presence of immunotoxins or uncon-
jugated toxins at concentrations of I nM. To determine the
cell-killing efficiencies of the immunotoxins in continuous
exposure experiments, untreated tumour cells were serially
diluted 10-fold in tissue culture medium and a sample of
100 LIl was plated in each of 12 wells of a microtitre plate. An
additonal 100 il of tissue culture medium containing different
concentrations of immunotoxin was added to each well and
the cells were then incubated for 21 days at 37°C under cell
culture conditions. Clonogenic growth was evaluated by
visually scoring the number of wells with at least one colony
that contained at least 50 cells. The plating efficiencies were
calculated with the Spearman estimator (Johnson & Brown,
1961). Diluent-treated cell cultures were used as controls for
calculating the surviving fractions in the various treated cul-
tures.
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Selection ofSW2 cells surviving continuous exposure to
immunotoxins
Clones of SW2 cells surviving continuous exposure to SEN7-
PE at 1 nM or to SEN7-bR at 0.1 nM in limiting dilution
clonogenic assays were expanded and tested for antigen ex-
pression by FACS analyses and for susceptibility to intoxica-
tion by immunotoxins and unconjugated toxins in [3H]leucine
incorporation assays.
Statistics
All data shown represent the mean of at least three indepen-
dent determinations. The Student's t-test was used to deter-
mine the significance of differences in the cell binding
activities. P-values <0.05 were taken as statistically sig-
nificant.
Results
Internalisation ofSEN7
To determine whether or not SEN7 was rapidly internalised,
SW2 cells were subjected to an internalisation assay using
SEN7 and a positive control antibody, SEN31, which recog-
nises the cluster 5a antigen on SCLC cells.
After 45 min at 0°C and 37°C, all of the MAb SEN7
remained on the cell surface (Figure la and b), whereas large
amounts of the control MAb SEN31 were detected within
the cells following incubation at 37°C (Figure lc). This
indicates that very little if any of the target epitope inter-
nalised upon exposure to SEN7.
Cell-binding activities ofimmunotoxins
In a competitive binding assay the ability of the immunotox-
ins SEN7-PE, SEN7-bR and SEN7-ricin A-chain to inhibit
the binding of FITC-labelled SEN7 to SW2 cells was
examined and compared directly with that of unmodified
SEN7.
As shown in Figure 2, binding of the labelled antibody was
half-maximally inhibited by 5 nM SEN7. The immunotoxins
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Figure 1 Internalisation of cell surface-bound MAb SEN7 by SW2 cells. Cells were incubated for 45 min at O'C a, or at 37'C b, in
the presence of saturating amounts of SEN7. Following fixation and permeabilisation, cell-associated antibody was visualised by
staining with rhodamine-labelled goat anti-mouse F(ab')2 IgG fragments either directly (a', b') or after stripping the cell surface
with an acid buffer (a", b"). In a positive control experiment cells were incubated at 37°C with the cluster 5a-specific MAb SEN31
and internalised antibody is shown following treatment ofcells without (c') and with (c") acid buffer. Photographs were taken from
cytospin preparations using a Zeiss LMS confocal laser microscope.IMMUNOTOXINS AGAINST SMALL CELL LUNG CANCER 35
inhibited the binding of FITC-labelled SEN7 to 50% at
concentrations of 9nM (SEN7-PE), 16nM (SEN7-bR) and
8 nM (SEN7-ricin A-chain). This reflects a 2-3-fold loss
compared with the unmodified antibody.
Cytotoxic activities ofimmunotoxins
The cytotoxic activities of the immunotoxins SEN7-PE,
SEN7-bR and SEN7-ricin A-chain were determined against
a panel of antigen-positive SCLC cell lines and antigen-
negative control cell lines in tissue culture during a 24 h
exposure in [3H]leucine incorporation assays (Table Ia).
The cytotoxic activitites of irrelevant (anti-CDl9) control
immunotoxins and of the corresponding unconjugated toxins
were determined in parallel (Table lb).
SEN7-PE and SEN7-bR were potently and selectively toxic
to the antigen-positive cell lines, inhibiting protein synthesis
by 50% compared with untreated control cells at concentra-
tions (IC.0) ranging between 22 pM and 85 pM and between
7.3 pM and 62 pM respectively. The activity against the
antigen-negative cell lines LXI and U1752 was more than
400- to 800-fold lower, as was the unspecific cytotoxic effect
of the corresponding control immunotoxins. The IC50 values
of the unconjugated toxins PE and bR ranged between
0.38 nM and 1.1 nM and between 0.75 nM and 4.6 nM respec-
tively. SEN7-ricin A-chain and unconjugated ricin A-chain
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Figure 2 Competition binding analyses of SEN7 immunotoxins and FITC-labelled SEN7 on SW2 cells. Cells were incubated with
varying concentrations of SEN7-PE a, SEN7-bR b, or SEN7-ricin A-chain c, in the presence of a fixed amount of FITC-labelled
SEN7 competitor at OC for 1 h. (@). The competition binding of unconjugated SEN7 (0) is shown for comparison. Data are
presented as the mean fluorescence intensities determined by FACS analyses.
TableIa CytotoxicactivitiesofSEN7immunotoxinsagainstSCLCcelllinesintissue
culture
IC50a (M)
Cell line SEN7-PE SEN7-bR SEN7-ricin A-chain
SW2 (2.2 ± 1.1) x 10-1" (7.9 ± 2.7) x 10-12 (2.2 ± 0.4) x 10-8
OHI (5.0 ± 1.8) x 10-1" (3.1 ± 2.0) x 10-"1 (3.3 ± 0.7) x 10-8
OH3 (2.6 ± 2.1) x 10-" (1.2 ± 0.3) x 10-" (1.6 ± 1.2) x 10-8
H60 (4.0 ± 1.4) x 10-" (3.8 ± 0.6) x 10-" (5.1 ± 2.3) x 10-8
N417 (8.5 ± 3.1) x 10-11 (6.2 ± 2.6) x 10-11 > 10-8
DC571.38 (5.4 ± 2.1) x 10-"1 (7.3 ± 2.2) x 10-12 > 10-8
LX1b (9.3 ± 3.0) x 10-9 (4.2 ± 1.9) x 10-9 > O-7
U1752b,c (6.4 ± 2.8) x 10 9 (2.6 ± 0.9) x 10 9 > 10-8
aMean ± s.d. from three independent experiments in terms oftoxin concentration.
bAntigen-negative cell line. cSquamous lung cancer cell line.
Table lb Cytotoxic activities of control (anti-CD19) immunotoxins and unconjugated toxins against SCLC cell lines in tissue culture
IC50a (M)
Cell line SJ25-CI-PE Anti-B4-bR SJ25-CI-ricin A-chain PE bR Ricin A-chain
SW2 (3.9 ± 2.2) x 10-9 (2.1 ± 0.9) x 10-9 (3.3 ± 0.5) x 10-8 (5.0 ± 2.2) x 10-10 (9.1 ± 2.5) x 10-10 (5.7 ± 2.6) x 10-8
OHI (8.5 ± 3.6) x 10-9 (2.7 ± 1.6) x 10-9 (2.1 ± 0.9) x 10-8 (1.1 ± 0.4) x 10-9 (2.5 ± 1.8) x 10-9 (4.3 ± 1.7) x 10-8
OH3 (5.9 ± 2.7) x 10-9 (9.5 ± 4.3) x 10-10 (1.7 ± 1.0) x 10-8 (7.2 ± 3.1) x 10-10 (1.3 ± 0.8) x 10-9 (5.2 ± 2.2) x 10-8
N417 ND (1.4 ± 0.8) x 10-9 > 10-8 ND ND ND
DC571.38 ND ND ND (5.2 ± 2.1) x 10-10 (7.5 ± 2.6) x 10-10 > 10-8
LXlb (7.0 ± 3.4) x 10-9 (1.9 ± 1.1) x 10-9 > 10-7 (6.9 ± 2.0) x 10-10 (2.8 ± 1.3) x 10-9 > l0o-
U1752bc ND ND ND (3.8 ± 1.9) x 10-10 (4.6 ± 2.1) x 10-9 >10-8
aMean ± s.d. fromthreeindependent experimentsintermsoftoxinconcentration.bAntigen-negative cellline.cSquamouslungcancercellline. ND,
not determined.
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were only weakly active against all cell lines tested
(IC50> 1OnM), indicating that SEN7 is not an efficient car-
rier of A-chain toxicity in the absence of internalisation and
translocation mediated by the toxin.
Specificity ofaction ofimmunotoxins
The specificity of action of SEN7-PE, SEN7-bR and
SEN7-ricin A-chain was examined using the SW2 cell line in
tissue culture. Figure 3 shows the representative concentra-
tion-activity curves obtained in [3H]leucine incorporation
assays with and without preincubation of cells with 1 ;LM
unconjugated SEN7 as blocking reagent.
SEN7-PE and SEN7-bR and the weakly cytotoxic SEN7-
ricin A-chain acted in a concentration-dependent fashion.
Without blocking the binding sites on the target cells with
unconjugated SEN7, the immunotoxins reduced [3H]leucine
incorporation as judged from ICm values (Table Ta). In con-
trast, blocking of the binding sites with an excess amount of
SEN7 reduced the cytotoxic effects of SEN7-PE and SEN7-
bR by about 500- and 200-fold respectively.
Potentiation ofimmunotoxins
The potentiating agents monensin, ammonium chloride and
chloroquine were tested for their abilities to enhance the
cytotoxic activity of SEN7-PE, SEN7-bR and SEN7-ricin
A-chain against SW2 cells and antigen-negative LXI control
cells in tissue culture. Control (anti-CD19) immunotoxins
were tested in parallel. Potentiators were used at concentra-
tions which inhibited [3H]leucine incorporation in the assays
less than 15%.
Ammonium chloride and chloroquine had no potentiating
effect on either of the immunotoxins (data not shown). As
shown in Table II monensin at a concentration of 80nM
drastically enhanced the antigen-specific activity of the ricin
immunoconjugates against SW2 cells. SEN7-ricin A-chain
was enhanced by 2,100-fold and SEN7-bR by 80-fold. This
potentiating effect of monensin was not entirely selective
because the activity against LXI cells was slightly enhanced:
27- (SEN7-bR) or 8-fold (SEN7-ricin A-chain). In addition,
unconjugated bR and ricin A-chain were each enhanced by
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Table II Cytotoxic activities of SEN7 immunotoxins, control
(anti-CD19) immunotoxins and unconjugated toxins in combination
withmonensinataconcentration of80 nMagainsttheSW2andtheLXI
cell lines in tissue culture
Potentiationfactor"
Cytotoxic agent SW2 LxIb
SEN7-PEC <0.5 <1
SEN7-bR 80 27
SEN7-ricin A-chain 2100 8
SJ25-C1-PEC <1 < I
Anti-B4-bR 29 22
SJ25-CI-ricin A-chain 6 9
PEc <0.5 <0.5
bR 45 34
Ricin A-chain 10 7
'IC5ointheabsence ofmonensindividedbytheICminthepresenceof
monensin. bAntigen-negative cellline.cNopotentiationobservedalsoat
lower concentrations of monensin.
between 34- and 45-fold and between 7- and 10-fold respec-
tively. Monensin at the same concentration (80 nM) slightly
inhibited the cytotoxic effects ofthe PE-immunotoxins and of
unconjugated PE (Table II) and could also not enhance
PE-mediated inhibition of [3H]leucine incorporation at lower
concentrations (data not shown).
Kinetics ofprotein synthesis inhibition by immunotoxins
The kinetics of protein synthesis inhibition by SEN7-PE and
SEN7-bR was determined by incubating SW2 cells in the
presence of the immunotoxins at concentrations of 1 nM and
measuring the effect of [3H]leucine incorporation. Uncon-
jugated bR and PE were used for comparison at equivalent
concentrations. Data are shown in Figure 4.
SEN7-bR intoxication proceeded rapidly following a 2 h
lag phase. Protein synthesis was reduced to 50% in a time
(tm) of 5.5 h and to 90% in a time (t1o) of 11 h. Similarly,
SEN7-PE was not significantly active during the first 2 h
after incubation. Thereafter, intoxication proceeded at a
slightly slower rate compared with SEN7-bR. The values for
b c
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Concentration of toxin (M)
Figure 3 Specificity of the toxic effects mediated by the SEN7 immunotoxins against SW2 cells in tissue culture. Cells were
preincubated with saturating amounts of unconjugated SEN7 at 37°C for I h. The immunotoxins SEN7-PE a, SEN7-bR b, and
SEN7-ricin A-chain c, were added to the cultures at varying concentrations and the cells were incubated for 20 h and for a further
4 h in the presence of [3H]leucine (-). The toxic effects mediated by the same SEN7 immunotoxins without preincubation with
SEN7 are shown for comparison (0). Data are expressed as the incorporation of [3Hjleucine as a percentage of control cultures
pretreated with SEN7 and present the mean; line bars, s.d.IMMUNOTOXINS AGAINST SMALL CELL LUNG CANCER 37
t5o and t1o were calculated as 6.5 h and 15 h respectively. At
equivalent concentrations the unconjugated toxins were
significantly less effective and the tio values were calculated as
8 h and 11 h respectively.
Cell-killing efficiencies ofimmunotoxins in limiting dilution
assays
Antigen-positive SW2 cells and antigen-negative LXI control
cells were continuously exposed to SEN7-PE or SEN7-bR
a
I I-n
4 8 12 16 20 24 28
b
IIj
4 8 12 16 20
Time of incubation (h)
24 28
Figure 4 Kinetics of protein synthesis inhibition by SEN7
immunotoxins. SW2 cells were incubated in the continuous
presence of either SEN7-PE a, or SEN7-bR b, at concentrations
of 1 nM for the stated times (0). The kinetics ofprotein synthesis
inhibition by unconjugated PE or bR is shown for comparison
(0). [3H]leucine was present in the cultures for at least 1 h. Data
are presented as the incorporation of [3H]leucine as a percentage
of untreated controls; lines bars, s.d.
and incubated for 21 days under tissue culture conditions.
Estimates of surviving clonogenic cells were made by a
limiting dilution assay. The killing efficiencies of the
immunotoxins were judged from the reduction in the number
of colonies compared with the untreated control cultures.
As shown in Figure 5, SEN7-PE reduced the surviving
fraction of clonogenic SW2 cells by more than 4 logs at a
concentration (1 nM) which eliminated less than 0.5 log of
clonogenic LX1 cells. SEN7-bR was even more potent and
killed up to 5 logs of SW2 cells at a concentration of 0.7 nM,
while LXI cells required up to 1,000-fold more drug for a
similar cell kill.
NCAM expression and susceptibility to SEN7 immunotoxins
ofSW2 cellspre-exposed in limiting dilution assays
The presence of the target epitope recognised by SEN7 was
quantitated by FACS analyses of SW2 cells which had sur-
vived continuous exposure to either 1 nM SEN7-PE or 0.1 nM
SEN7-bR in limiting dilution assays. Staining with SEN36,
which recognises a different epitope on NCAM, was done for
comparison. In addition, the susceptibility of the cells to the
immunotoxins and to unconjugated PE or bR was examined
in [3H]leucine incorporation assays. Non-pretreated SW2 cells
were used as controls.
As shown in Table III, SEN7-PE-pretreated SW2 cells and
non-pretreated SW2 control cells exhibited identical fluor-
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Figure 5 Cell-killing efficiency of SEN7 immunotoxins against
SCLC cells in tissue culture. SW2 cells (0, *) or LXI control
cells (0, *) were incubated in the continuous presence of SEN7-
PE (open symbols) or SEN7-bR (closed symbols) in limiting
dilution clonogenic assays. Data are presented as surviving frac-
tions, which were calculated by comparison with diluent-treated
control cultures.
TableIII Relative levelsofSEN7andSEN36bindingandcytotoxicactivitiesofSEN7immunotoxinsandunconjugated toxins
against clonogenic SW2 cells pre-exposed to the immunotoxins in limiting dilution assays
SW2 cells Relative MFI ICsob (M)
pre-exposed toa SEN7/SEN36 SEN7-PE SEN7-bR PE bR
325/378 (1.5 ± 0.4) x 10-11 (7.5 ± 2.3) x 10-12 (5.3 ± 2.0) x 10-10 (8.4 ± 2.9) x 10-10
SEN7-PE 333/371 (1.9 ± 1.1) x 10-9 (8.2 ± 2.7) x 10-12 (4.9 ± 2.2) x 10-9 (7.4 ± 2.1) x 10-'°
SEN7-bR 98/109 (5.3 ± 2.8) x 10-9 (8.5 ± 1.9) x 10-10 (5.9 ± 2.4) x 1010 (9.0 ± 3.2) x 10-10
aCellspretreatedwithimmunotoxins inlimiting dilutionassays.bMean ± s.d. fromthreeindependentexperimentsin termsof
toxin concentration. MFI, mean fluorescence intensity (average channel value).
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escence intensities after indirect staining with SEN7 or
SEN36, indicating that identical amounts of NCAM were
expressed on their surfaces. Compared with the control cells,
SEN7-PE pretreated cells were equally sensitive to SEN7-bR
and unconjugated bR, but more than 100- and 10-fold less
susceptible to SEN7-PE and PE intoxication respectively. In
contrast, SW2 cells which had survived pretreatment with
SEN7-bR in limiting dilution assays did not stain sig-
nificantly with the antibodies, indicating that NCAM-
deficient tumour cells or cells expressing very low levels of
antigen (below the detection threshold of the assay) had been
selected in the cultures. Accordingly, these cells were not
selectively killed by either immunotoxin but were equally
sensitive to unconjugated PE or bR compared with the cont-
rol cells. Reexpression of NCAM gradually occurred during
a time interval of 6 weeks in tissue culture in the absence of
selective pressure (data not shown).
Discussion
Ricin A-chain immunotoxins directed against antigens of the
clusters w4 and 5a have shown substantial and selective
cytotoxic and therapeutic potency against SCLC cells in pre-
clinical studies in vitro and in vivo (Wawrzynczak et al., 1990;
1991; Derbyshire et al., 1992a; Zangemeister-Wittke et al.,
1993a,b). In contrast, ricin A-chain immunotoxins directed
against the cluster 1 antigen which corresponds to the neural
cell adhesion molecule (NCAM) could not prove potent
cytotoxic agents (Wawrzynczak et al., 1991; Derbyshire et al.,
1992a). This is consistent with our finding that NCAM,
which was complexed on the target cell surface with the
MAb SEN7, was not well internalised and remained on the
cell surface. Immunotoxins act on intracellular targets, conse-
quently internalisation is a major requirement for their
cytotoxic activity. We have coupled the whole toxin
molecules of native ricin or Pseudomonas exotoxin A (PE) to
the MAb SEN7 because these toxins possess the ability to
promote internalisation of the conjugates via their natural
receptors on the cell surface. In order to warrant a high
degree of selectivity the binding activities of the toxins were
substantially reduced. With ricin this was achieved by
covalently blocking the galactose binding sites of the B-chain
with affinity ligands, resulting in a blocked ricin molecule
(bR) with a more than 3,500-fold lower binding affinity and a
1,000-fold lower non-specific toxicity compared with native
ricin (Lambert et al., 1991a,b). Native PE was conjugated to
SEN7 via a thioether linkage (Morgan et al., 1990; Fitz-
Gerald et al., 1990). Both SEN7-bR and SEN7-PE are
immunologically distinct molecules inhibiting protein syn-
thesis in cells by acting on different cellular targets.
Therefore, their combination could help to (1) circumvent
neutralising immune responses directed against the toxin
moiety and (2) achieve higher cytotoxic potency against
tumour cells with different sensitivities to different toxins.
Whereas the susceptibility of SCLC cell lines to ricin
immunotoxins is well documented, immunotoxins against
SCLC which employ the toxic moiety of PE have not been
previously described. SEN7-bR and SEN7-PE were potently
and selectively active against various SCLC cell lines of both
classic and variant morphologies with IC50 values ranging
between 7 and 85 pM. With each immunotoxin, intoxication
of target cells proceeded rapidly following a 2 h lag phase.
The potency of the bR conjugate was approximately 1 log
higher than that of the PE conjugate as judged by the
unspecific killing ofantigen-negative tumour cells. The latter,
on the other hand, was more selective. Although binding of
the toxin moieties to their natural receptors efficiently pro- moted internalisation and cytotoxic action of the SEN7
immunotoxins, the unconjugated toxins alone were sig- nificantly less effective. One might speculate that binding of
SEN7 to NCAM directs the toxins in close proximity to their
natural receptors and induces the formation of high-affinity
receptor-ligand complexes which are more likely to be rapid-
ly and efficiently transported to the translocation compart-
ment.
The cytotoxic effects of the ricin immunotoxins could be
drastically enhanced by monensin. Potentiation of SEN7-
ricin A-chain, in particular, indicates that even in the absence
of the B-chain at least a small proportion of the NCAM
epitope was internalised by the cells, albeit in a fashion not
conducive to efficient A-chain translocation to the cytosol.
The extreme cytotoxic activity and the lower rate ofpotentia-
tion of SEN7-bR by monensin suggest that the B-chain alone
is sufficient to fulfil the requirements for efficient intoxication
of target cells. In contrast to the ricin immunotoxins, monen-
sin inhibited the action of SEN7-PE. This might reflect the
difference in the translocation compartments for the catalytic
subunits of ricin and PE. Whereas ricin translocates in the
trans-Golgi network (Olsnes et al., 1989; Sandvig et al.,
1991), translocation of PE seems to be confined to the
endoplasmic reticulum (FitzGerald & Pastan, 1992). In view
of recent progress in enhancing the potentiating effect of
monensin in vivo (Hertler et al., 1989; Griffin et al., 1993),
ricin derivatives might prove advantageous agents in cases
where immunotargeting is directed against non-internalising
cell-surface antigens. The lack of potentiation of SEN7
immunotoxins by lysosomotropic amines suggests that
lysosomal degradation was not a factor limiting the cytotoxic
potency of these agents.
Despite the stable and frequent expression of NCAM on
most SCLC cells, NCAM-deficient tumour cells or at least
cells expressing very low levels of antigen emerged under the
selection pressure exerted by SEN7-bR. Re-expression of
NCAM occurred during a time interval of 6 weeks in tissue
culture in the absence of the immunotoxin, indicating that
antigen deficiency was acquired in response to the selection
process. In contrast, cells pretreated with SEN7-PE fully
retained their NCAM expression pattern and their sensitivity
to SEN7-bR but were more than 10-fold less susceptible to
intoxication by PE. The different mechanisms of resistance
which were observed following pretreatment with the
immunotoxins coincide with the different mechanisms of
action of the corresponding catalytic domains. Ricin has an
N-glycosidase activity which is not reversible (Endo et al.,
1987). Similarly, the ADP-ribosyl transferase activity of PE is
essentially irreversible under physiological conditions (Iglew-
ski et al., 1977). However, resistance to PE can emerge as a
result of the selection of elongation factor 2 variants which
are less accessible to the toxin. Further mechanisms which
might contribute to the resistance of SEN7-PE-pretreated
cells include inherent differences in their ability to internalise
and process the immunotoxin and cell-surface alterations that
impede the passage of the toxin across the membrane (Godal
et al., 1986; Goldmacher et al., 1987). The capability of
SCLC cells to modulate prominent cell-surface antigens dur-
ing antibody-based immunotherapy and to acquire resistance
to toxins and chemotherapeutic drugs strongly supports their
high evolutionary potential. As a rationale, a combination of
alternative therapeutic strategies should include immunotox-
ins which employ not only different toxins but also different
target antigens in order to achieve maximal efficacy. Alto-
gether, since the SCLC cells were less able to develop resis-
tance to ricin as compared with PE, ricin seems to be a more
potent cytotoxic agent in this tumour system.
In conclusion, we describe the potent and selective
cytotoxic activities of immunotoxins made with the MAb
SEN7, recognising a new NCAM epitope on SCLC cells. The
lack of significant spontaneous endocytosis of cell surface-
bound SEN7 implies that in order to make a selective and
potent immunotoxin against NCAM the toxin moiety must
be capable of promoting internalisation and translocation by
weakened receptor-ligand interactions on the cell surface.
This requirement is fulfilled by bR and by PE when coupled
to the MAb via a thioether linkage.
We would like to thank Dr M. Kressel for performing laser micro-
scopy. This work was supported by the Robert Wenner Award of
the Swiss Cancer League and the Krebsforschung Schweiz.IMMUNOTOXINS AGAINST SMALL CELL LUNG CANCER 39
References
BLAKEY, D.C. & THORPE, P.E (1988). An overview of therapy with
immunotoxins containing ricin or its A-chain. Anti. Immuno.
Radiopharma., 1, 1-16.
CARBONE, D.P., KOROS, A.M.C., LINNOILA, R.I., JEWETT, P. & GAZ-
DAR, A.F. (1991). Neural cell adhesion molecule expression and
messenger RNA splicing patterns in lung cancer cell lines are
correlated with neuroendocrine phenotype and growth mor-
phology. Cancer Res., 51, 6142-6149.
CARNEY, D.N. & DE LEI, L. (1988). Lung cancer biology. Semin.
Oncol., 3, 199-214.
CHANG, K., PAI, L.H., BATRA, J.K., PASTAN, I. & WILLINGHAM,
M.C. (1992). Characterization of the antigen (CAKI) recognized
by monoclonal antibody KI present on ovarian cancers and
normal mesothelium. Cancer Res., 52, 181-186.
CUMBER, A.J., FORRESTER, J.A., FOXWELL, B.M.J., ROSS, W.C.J. &
THORPE, P.E. (1985). Preparation of antibody-toxin conjugates.
Methods Enzymol., 112, 207-225.
DERBYSHIRE, A.J., STAHEL, R.A. & WAWRZYNCZAK, E.J. (1992a).
Cytotoxic properties of a ricin A-chain immunotoxin recognising
the cluster-5A antigen associated with human small-cell lung
cancer. Cancer Immunol. Immunother., 35, 417-420.
DERBYSHIRE, E.J., STAHEL, R.A. & WAWRZYNCZAK, E.J. (1992b).
Potentiation of a weakly active ricin A-chain immunotoxin recog-
nizing the neural cell adhesion molecule. Clin. Exp. Immunol., 89,
336-340.
ENDO, Y., MITSUI, K., MOTIZUKI, M. & TSURUGI, K. (1987). The
mechanism of action of ricin and related toxic lectins on
eukaryotic ribosomes. J. Biol. Chem., 262, 5908-5913.
FITZGERALD, D., WILLINGHAM, M., CARDARELLI, C.O., HAM-
ADA, H., TSURUO, T., GOTTESMAN, M.M. & PASTAN, I. (1987).
A monoclonal antibody-pseudomonas toxin conjugate that
specifically kills multidrug-resistant cells. Proc. Nati Acad. Sci.
USA, 84, 4288-4292.
FITZGERALD, D., IDZIOREK, T., BATRA, J.K., WILLINGHAM, M. &
PASTAN, I. (1990). Antitumour activity of a thioether-linked
immunotoxin: OVB3-PE. Bioconjugate Chem., 1, 264-268.
FITZGERALD, D.J. & PASTAN, I. (1992). Pseudomonas exotoxin:
recombinant conjugates as therapeutic agents. Biochem. Soc.
Trans., 20, 731-733.
GODAL, A., FODSTAD, O., MORGAN, A.C. & PIHL, A. (1986). Human
melanoma cell lines showing striking inherent differences in sen-
sitivity to immunotoxins containing holotoxins. J. Natl Cancer
Inst., 77, 1247-1253.
GOLDMACHER, V.S., ANDERSON, J., SCHULZ, M.L., BLATTLER,
W.A. & LAMBERT, J.M. (1987). Somatic cell mutants resistant to
ricin, diphtheria toxin, and to immunotoxins. J. Biol. Chem., 262,
3205-3209.
GRIFFIN, T., RYBAK, M.E., RECHT, L., SINGH, M., SALINI, A. &
RASO, V. (1993). Potentiation of antitumour immunotoxins by
liposomal monensin. J. Natl Cancer Inst., 85, 292-298.
HERTLER, A.A., SCHLOSSMAN, D.M., BOROWITZ, H.J., BLYTHMAN,
H.E., CASELLAS, P. & FRANKEL, A.E. (1989). An anti-CD5
immunotoxin for chronic lymphocytic leukemia: enhancement of
cytotoxicity with human serum albumin-monensin. Int. J.
Cancer, 43, 215-219.
IGLEWSKI, B.H., LIU, P.V. & KABAT, D. (1977). Mechanism of action
of pseudomonas aeruginosa exotoxin A: adenosine diphosphate-
ribosylation of mammalian elongation factor 2 in vitro and in
vivo. Infect. Immun., 15, 138-144.
JOHNSON, E.A. & BROWN, B.W. (1961). The spearman estimator for
serial dilution assays. Biometrics, 30, 79-88.
KOUNNAS, M.Z., MORRIS, R.E., THOMPSON, M.R., FITZGERALD,
D.J., STRICKLAND, D.K. & SAELINGER, C.B. (1992). The M2-
macroglobulin receptor/low density lipoprotein receptor-related
protein binds and internalizes pseudomonas exotoxin A. J. Biol.
Chem., 267, 12420-12423.
LAMBERT, J.M., MCINTYRE, G., GAUTHIER, M.N., ZULLO, D., RAO,
V., STEEVES, R.M., GOLDMACHER, V.S. & BLATTLER, W.A.
(1991a). The galactose binding sites of the cytotoxic lectin ricin
can be chemically blocked in high yield with reactive ligands
prepared by chemical modification of glycopeptides containing
triantennary N-linked oligosaccharides. Biochemistry, 30, 3234-
3247.
LAMBERT, J.M., GOLDMACHER, V.S., COLLINSON, A.R., NADLER,
L.M. & BLATTLER, W.A. (1991b). An immunotoxin prepared with
blocked ricin: a natural plant toxin adapted for therapeutic use.
Cancer Res., 51, 6236-6242.
LYNCH, T.J., CORAL, F., SHEFNER, J., ELIAS, A.D., SKARIN, A.,
MENTZER, S., SUGARBAKER, D., EPSTEIN, C., BLATTLER, W.A.,
COLLINSON, A.R. & RITZ, J. (1993). Phase one trial of the novel
immunotoxin N901-blocked ricin (N901-BR): demonstration of
clinical activity in small cell lung cancer. ASCO, 12, 293.
MOOLENAAR, C.E., MULLER, E.J., SCHOL, D.J., FIGDOR, C.G.,
BOCK, E., BITTER, S.D. & MICHALIDES, R.J. (1990). Expression
of neural cell adhesion molecule-related sialoglycoprotein in small
cell lung cancer and neuroblastoma cell lines H69 and CHP-212.
Cancer Res., 50, 1102-1106.
MORGAN, A.C., SIVAM, G., BEAUMIER, P., MCINTYRE, R., BJORN,
M. & ABRAMS, P.G. (1990). Immunotoxins of pseudomonas
exotoxin A (PE): effect of linkage on conjugate yield, potency,
selectivity and toxicity. Mol. Immunol., 27, 273-282.
OLSNES, S., SANDVIG, K., PETERSEN, O.W. & VAN DEURS, B. (1989).
Immunotoxins - entry into cells and mechanisms of action.
Immunol. Today, 10, 291-295.
PASTAN, I. & FITZGERALD, D. (1991). Recombinant toxins for
cancer treatment. Science, 254, 1173-1177.
PATEL, K., BOURNE, S., PHIMISTER, B., COAKHAM, H. & KEM-
SHEAD, J.T. (1990). Presence of neural cell adhesion molecule on
human embryonic and brain tumours. Biochem. Soc. Trans., 18,
408-410.
ROTHBARD, J.B., BRACKENBURY, R., CUNNINGHAM, B. & EDEL-
MAN, G. (1982). Differences in the carbohydrate structures of
neural cell adhesion molecules from adult and embryonic chicken
brains. J. Biol. Chem., 257, 11064-11069.
ROUGON, G., DEAGOSTINI-BAZIN, H., HIRN, M. & GORIDIS, C.
(1982). Tissue and development stage specific forms of neural cell
surface antigen linked to differences in glycosylation of a com-
mon polypeptide. EMBO J., 1, 1239-1244.
SANDVIG, K., PRYDZ, K., HANSEN, S.H. & VAN DEURS, B. (1991).
Ricin transport in brefeldin A-treated cells: correlation between
golgi structure and toxic effect. J. Cell Biol., 115, 971-981.
SHAH, S.A., HALLORAN, P.M., FERRIS, C.A., LEVINE, B.A., BOUR-
RET, L.A., GOLDMACHER, V.S. & BLATTLER, W.A. (1993). Anti-
B4-blocked ricin immunotoxin shows therapeutic efficacy in four
different SCID mouse tumor models. Cancer Res., 53, 1360-1367.
SOUHAMI, R.L., BEVERLEY, P.C.L., BOBROW, L.G. & LEDERMANN,
J.A. (1991). Antigens of lung cancer: results of the second interna-
tional workshop on lung cancer antigens. J. Natl Cancer Inst., 83,
609-612.
WAIBEL, R., MANNHART, M., O'HARA, C.J., BROCKLEHURST, C.,
ZANGEMEISTER-WITTKE, U., SCHENKER, T., LEHMANN, H.P.,
WEBER, E. & STAHEL, R.A. (1993). Monoclonal antibody SEN7
recognizes a new epitope on the neural cell adhesion molecule on
small cell lung cancer but not on lymphocytes. Cancer Res. (in
press).
WAWRZYNCZAK, E.J., DERBYSHIRE, E.J., HENRY, R.V., PARNELL,
G.D., SMITH, A., WAIBEL, R. & STAHEL, R.A. (1990). Selective
cytotoxic effects of a ricin A-chain immunotoxin made with the
monoclonal antibody SWAl 1 recognising a human small cell
lung cancer antigen. Br. J. Cancer, 62, 410-414.
WAWRZYNCZAK, E.J., DERBYSHIRE, E.J., HENRY, R.V., PARNELL,
G.D., SMITH, A., WAIBEL, R. & STAHEL, R.A. (1991). Cytotoxic
activity of ricin A-chain immunotoxins recognising cluster 1, w4
and 5A antigens associated with human small cell lung cancer.
Br. J. Cancer, 63, 71-73.
ZANGEMEISTER-WITTKE, U., LEHMANN, H.P., WAIBEL, R., WAW-
RZYNCZAK, E.J. & STAHEL, R.A. (1993a). Action of a
CD24-specific deglycosylated ricin-A-chain immunotoxin in con-
ventional and novel models of small-cell-lung-cancer xenograft.
Int. J. Cancer, 53, 521-528.
ZANGEMEISTER-WITTKE, U., COLLINSON, A.R., FISCH, I., JONES,
R.M.L., WAIBEL, R., LEHMAN, H.P. & STAHEL, R.A. (1992b).
Anti-tumor activity of a blocked ricin immunotoxin with
specificity against the cluster-SA antigen associated with small-
cell lung cancer. Int. J. Cancer, 54, 1028-1035.